Recently, MUC1 was shown to promote PDL1 expression on tumor colon cells through the recruitment of inflammatory cytokines and subsequently inhibit the antitumor immune response via the PDL1/PD1 signaling pathway, providing a foundation for the application of PDL1 inhibitors in MUC1‐positive colon cancer [46]. This evidence concerns the gene MUC1 and neoplasm.